Lv1
80 积分 2025-01-22 加入
The depth of response was associated with the progression-free survival in advanced non-small cell lung cancer patients treated with EGFR-TKI
2个月前
已关闭
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
2个月前
已完结
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
2个月前
已完结
Epigenetic upregulation of PSD-95 contributes to the rewarding behavior by morphine conditioning
3个月前
已完结
Impact of Preoperative Hepatitis B Virus Levels on Prognosis After Primary and Repeat Hepatectomies for Hepatocellular Carcinoma Patients—a Retrospective Study
3个月前
已完结
Antimicrobial Prophylaxis for Adult Patients with Cancer-Related Immunosuppression Guideline
4个月前
已关闭
[Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)]
4个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已关闭
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC
5个月前
已关闭
皖公网安备34019202002308
